3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hepatic Encephalopathy
1
Head and Neck Neoplasms
1
Emergencies
1
Critical Illness
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
30
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
Glucose
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts